imatinib

P3, N=54, Active, not recruiting, Deciphera Pharmaceuticals, LLC | Recruiting --> Active, not recruiting | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Dec 2027

Notably, this is the first report of ArtiSential articulated forceps utilized in TAMIS, demonstrating their innovative potential in enhancing surgical precision and outcomes in challenging pelvic procedures. The online version contains supplementary material available at 10.1007/s13691-025-00786-7.

Most of these hypoglycemic effects were observed during the clinical use of imatinib, dasatinib, erlotinib, and sunitinib in cancer patients with diagnosis of DM. The use of these antineoplastic agents in patients with DM and a diagnosis of cancer shows that these agents have the ability to lower blood glucose, which can be associated with tapering down or discontinuing the use of anti-diabetic treatment. The online version contains supplementary material available at 10.1007/s40200-025-01811-5.

Oral melanocytic neoplasms are rare and have distinct clinicopathological features. Despite this, a gap exists in molecular data regarding ODN and AMP. Conversely, OMN and OMM have distinct profiles; in particular, the latter may benefit modestly from tyrosine kinase inhibitor treatment, as KIT and BRAF mutations are sensitive to imatinib and vemurafenib, respectively.

A fragment-assisted screen then delivered a phenalene-dicarbonitrile chemotype, S1g-2, and optimized analogs that displace Bim with sub-micromolar potency, dismantle Hsp70-client hubs, and resensitize resistant xenografts to imatinib or tamoxifen without global proteostasis collapse. Future directions include covalent or macrocyclic wedges, degrader hybrids, and adaptive pulse-dose regimens guided by proximity-ligation assays. Collectively, chemical disarming of the Hsp70-Bim alliance exemplifies how precision targeting of chaperone PPIs can recalibrate apoptotic thresholds and unlock new therapeutic space in oncology.

Cardiac involvement in hypereosinophilic syndromes requires multidisciplinary management combining cytoreductive therapy, anticoagulation when thrombus is present, and serial cardiac magnetic resonance. Testing for FIP1L1-platelet-derived growth factor receptor α is disease-defining and therapy-guiding given the marked response to imatinib.

Primary gallbladder EGISTs are exceedingly rare, with insidious onset and nonspecific clinical manifestations. Histopathological examination combined with immunohistochemistry remains the cornerstone of definitive diagnosis.

The rare genetic co-occurrence of t(15;17)/PML::RARA and t(9;22)/BCR::ABL1 translocations may be identified in a single patient with acute promyelocytic leukaemia (APL).Successful induction using all-trans retinoic acid (ATRA) together with imatinib achieved effective control of both leukemic clones.The patient demonstrated rapid haematologic remission and favourable clinical recovery, suggesting a positive outcome with this therapeutic approach.

Since then, four other tyrosine kinase inhibitors (TKIs), dasatinib, nilotinib, bosutinib and most recently asciminib, have garnered approval for frontline management of CML-CP. With limited prospective comparisons between the 2G-TKIs and similar survival outcomes with imatinib compared to 2G-TKIs, the selection of a TKI for patients with newly diagnosed CML-CP must be individualized to the needs of that specific patient. Important factors to consider when choosing a drug include patient related factors (age, comorbidities, lifestyle considerations, quality of life, patient preferences, shared-decision making and whether treatment free remission [TFR] is a goal), disease related factors (risk stratification, transcript type, presence of high risk gene mutations such as ASXL1) and drug related factors (major molecular response rates with each TKI, adverse events, rates of treatment discontinuation and TFR rates).

Since 2004, patients receiving imatinib with relapse in non-marrow sites were given dasatinib to preserve control of leukemic marrow. Dasatinib is a potentially practice-changing targeted therapy for EML. Finding and eradicating EML could increase the possibility of lengthy disease-free survival.

However, the toxicity and resistance associated with the use of imatinib, a first-generation Bcr-Abl inhibitor, in cases where the T315I mutation exists, necessitates the need for new tyrosine kinase inhibitors...However, investigating different combined scaffolds enhances the chance of successfully developing novel drug candidates. Overall, the information provided in this review can be beneficial to researchers with an interest in chronic myeloid leukemia and tyrosine kinase inhibitors.

P2, N=60, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting